Acquisition of BioCell Lugano, Switzerland

FamiCord Group acquired BioCell Lugano, which includes a modern laboratory in Switzerland. This is another important step towards expanding the scope of activities in western Europe, further enhancing FamiCord’s ability to offer innovative stem cell banking and regenerative medicine solutions across the continent.

The laboratory developed and started to commercialize technology of banking perinatal tissues such as placental villi and amniotic fluid cells. FamiCord plans to further expand BioCell Lugano laboratory capabilities, which currently serves B2B clients in Italy and Egypt. Company plans to expand this activity to offer cord blood banking which currently is not in the scope of BioCell services.

Recently added

06 September 2024 Dr Tomasz Baran – FamiCord Vicepresident – speaks on cord blood banking at world’s largest cord blood conference Tomasz Baran, MD, MBA, Vice President of FamiCord Group, recently shared his expertise on cord blood banking at the world’s largest cord blood conference... Read more
15 July 2024 Expanison of cord blood stem cells as a chance for cancer patients Cord blood stem cells are used in medicine for treatment of over 80 different diseases such as leukemias, lymphomas and sickle cell anaemia for over 30 years. It has also been proven that... Read more